These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 19049265

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
    Sosa AB, Epstein SP, Asbell PA.
    Cornea; 2008 Sep; 27(8):930-4. PubMed ID: 18724156
    [Abstract] [Full Text] [Related]

  • 43. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW.
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [Abstract] [Full Text] [Related]

  • 44. Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
    Tsai TH, Chen WL, Hu FR.
    Eye (Lond); 2010 May; 24(5):909-17. PubMed ID: 19648900
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T, Hori T, Sugimori G, Yamano Y.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [Abstract] [Full Text] [Related]

  • 48. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
    Wacke R, Förster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B.
    J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
    [Abstract] [Full Text] [Related]

  • 49. Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes.
    Yamada M, Ishikawa K, Mochizuki H, Kawai M.
    Acta Ophthalmol Scand; 2006 Apr; 84(2):192-6. PubMed ID: 16637835
    [Abstract] [Full Text] [Related]

  • 50. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
    Stein GE, Schooley S.
    Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
    [Abstract] [Full Text] [Related]

  • 51. Penetration of newer quinolones in the empyema fluid.
    Liapakis IE, Kottakis I, Tzatzarakis MN, Tsatsakis AM, Pitiakoudis MS, Ypsilantis P, Light RW, Simopoulos CE, Bouros DE.
    Eur Respir J; 2004 Sep; 24(3):466-70. PubMed ID: 15358708
    [Abstract] [Full Text] [Related]

  • 52. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
    Metallidis S, Charokopos N, Nikolaidis J, Alexiadou E, Lazaraki G, Koumentaki E, Tsona A, Theodoridis G, Nikolaidis P.
    Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. [The uptake of fluoroquinolone agent drugs by cultured human conjunctival epithelial cells and cultured SIRC rabbit corneal cells].
    Fukuda M, Yoshitake Y, Sasaki K.
    Nippon Ganka Gakkai Zasshi; 1999 Aug; 103(8):576-9. PubMed ID: 10466328
    [Abstract] [Full Text] [Related]

  • 55. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, Arvis P, Landreau V, Saux MC.
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [Abstract] [Full Text] [Related]

  • 56. Penetration of gatifloxacin eye drops into the aqueous humor in humans.
    Teshigawara T, Hata S, Hayashi T, Watanabe Y, Itoh Y, Hitoi K, Mizuki N.
    Ocul Immunol Inflamm; 2007 Dec; 15(4):309-13. PubMed ID: 17763128
    [Abstract] [Full Text] [Related]

  • 57. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [Abstract] [Full Text] [Related]

  • 58. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R.
    Int J Tuberc Lung Dis; 2006 Jun 15; 10(6):605-12. PubMed ID: 16776446
    [Abstract] [Full Text] [Related]

  • 59. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
    Robertson SM, Curtis MA, Schlech BA, Rusinko A, Owen GR, Dembinska O, Liao J, Dahlin DC.
    Surv Ophthalmol; 2005 Nov 15; 50 Suppl 1():S32-45. PubMed ID: 16257309
    [Abstract] [Full Text] [Related]

  • 60. Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
    Yanagihara K, Fukuda Y, Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, Kadota J, Tashiro T, Murata I, Kohno S.
    Chemotherapy; 2004 Jun 15; 50(3):107-12. PubMed ID: 15282438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.